Skip to Content
  • Previous Rank
  • Revenues ($M)
  • Revenue Percent Change
  • Profits ($M)
  • Profits Percent Change
  • Market Value (as of March 31, 2015)

Sales dropped and profit plummeted for Pfizer in 2014 due to the strong dollar and loss of patent protection for drugs like Celebrex, the blockbuster pain medication, and Viagra. The pharma giant made several unsuccessful bids to get bigger—and land a tax-lowering inversion deal—by buying a competitor, first courting big, British AstraZeneca and then Ireland’s Actavis. Left to its own portfolio and pipeline for now, the company did well by a number of drugs including Lyrica, its fibromyalgia med and its Prevnar vaccine, and is optimistic about oncology drugs coming down its pipeline.

Company Info

Ian C. Read
Health Care
HQ Location
New York, NY
Years on List21
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)49,605-7.8%
Profits ($M)9,135-58.5%
Total Stockholder Equity71,301-
Market Value (as of March 31, 2015)213,622-

Profit Ratios

Profit as % of Revenues18.4%
Profits as % of Assets5.4%
Profits as % of Stockholder Equity12.8%

Earnings Per Share (last fiscal year)

Earnings Per Share ($)1.42
EPS % Change (from 2013)-55.5%
EPS % Change (5 year annual rate)2.9%
EPS % Change (10 year annual rate)-0.5%

Total Return

Total Return to Investors (2014)5.2%
Total Return to Investors (5 year, annualized)15.7%
Total Return to Investors (10 year, annualized)5.9%